Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2020-005122-28
    Sponsor's Protocol Code Number:AB18001
    National Competent Authority:Italy - Italian Medicines Agency
    Clinical Trial Type:EEA CTA
    Trial Status:Prematurely Ended
    Date on which this record was first entered in the EudraCT database:2024-09-23
    Trial results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedItaly - Italian Medicines Agency
    A.2EudraCT number2020-005122-28
    A.3Full title of the trial
    A Phase 1/2 Study to Assess the Safety, Pharmacokinetics, and Efficacy of Daily Intravenous of AB8939 in patients with Relapsed/Refractory Acute Myeloid Leukemia
    Studio clinico di fase 1/2 per la valutazione della sicurezza, della farmacocinetica e dell’efficacia della somministrazione endovenosa giornaliera di AB8939 in pazienti affetti/e da leucemia mieloide acuta recidivante/refrattaria
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    Study to Assess the Safety, Pharmacokinetics, and Efficacy of AB8939 in patients with Relapsed/Refractory Acute Myeloid Leukemia
    Studio clinico di fase 1/2 per la valutazione della sicurezza, della farmacocinetica e dell’efficacia della somministrazione endovenosa giornaliera di AB8939 in pazienti affetti/e da leucemia mieloide acuta recidivante/refrattaria
    A.3.2Name or abbreviated title of the trial where available
    Relapsed/Refractory Acute Myeloid Leukemia
    AB18001
    A.4.1Sponsor's protocol code numberAB18001
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorAB SCIENCE
    B.1.3.4CountryFrance
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportAB Science
    B.4.2CountryFrance
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationAB Science
    B.5.2Functional name of contact pointCEO
    B.5.3 Address:
    B.5.3.1Street Address3 Avenue George V
    B.5.3.2Town/ cityParis
    B.5.3.3Post code75008
    B.5.3.4CountryFrance
    B.5.4Telephone number33147201261
    B.5.6E-mailregulatoryaffairs@ab-science.com
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product name1-{4-[2-(5-ethoxymethyl-2-methylphenylamino)- oxazol-5-yl]-phenyl}- imidazolidin-2-one
    D.3.2Product code [AB8939]
    D.3.4Pharmaceutical form Solution for infusion
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPIntravenous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNAB8939
    D.3.9.2Current sponsor codeAB8939
    D.3.9.3Other descriptive name1-{4-[2-(5-ethoxymethyl-2-methyl-phenylamino)-oxazol-5-yl]-phenyl}-imidazolidin- 2-one
    D.3.9.4EV Substance CodeSUB197706
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number20
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product Information not present in EudraCT
    D.3.11.3.2Gene therapy medical product Information not present in EudraCT
    D.3.11.3.3Tissue Engineered Product Information not present in EudraCT
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) Information not present in EudraCT
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product Information not present in EudraCT
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 2
    D.1.2 and D.1.3IMP RoleComparator
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.2Country which granted the Marketing AuthorisationItaly
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.4Pharmaceutical form Powder and suspension for suspension for injection
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPSubcutaneous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNAZACITIDINA
    D.3.9.1CAS number 320-67-2
    D.3.9.2Current sponsor codena
    D.3.9.3Other descriptive namena
    D.3.9.4EV Substance CodeSUB05624MIG
    D.3.10 Strength
    D.3.10.1Concentration unit µg/ml microgram(s)/millilitre
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number25
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product Information not present in EudraCT
    D.3.11.3.2Gene therapy medical product Information not present in EudraCT
    D.3.11.3.3Tissue Engineered Product Information not present in EudraCT
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) Information not present in EudraCT
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product Information not present in EudraCT
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Relapsed/Refractory Acute Myeloid Leukemia
    leucemia mieloide acuta recidivante/refrattaria
    E.1.1.1Medical condition in easily understood language
    Relapsed/Refractory Acute Myeloid Leukemia
    leucemia mieloide acuta recidivante/refrattaria
    E.1.1.2Therapeutic area Diseases [C] - Cancer [C04]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 21.1
    E.1.2Level PT
    E.1.2Classification code 10081513
    E.1.2Term Acute myeloid leukaemia refractory
    E.1.2System Organ Class 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
    E.1.3Condition being studied is a rare disease Yes
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    To define the safety and tolerability of AB8939 in patients with refractory or relapsed AML and
    MDS by determining the dose-limiting toxicities, the maximum tolerated dose (MTD) and the
    recommended dose for dose expansion study.
    Definire la sicurezza e la tollerabilità di AB8939 in pazienti affetti/e da leucemia mieloide acuta refrattaria o recidivante determinando le tossicità dose-limitanti la dose massima tollerata (MTD) e la dose raccomandata per lo studio con espansione.
    E.2.2Secondary objectives of the trial
    To determine the pharmacokinetic profile in the function of dose.
    To assess early efficacy.
    Determinare il profilo farmacocinetico in funzione della dose.
    Valutare l’efficacia precoce.
    E.2.3Trial contains a sub-study Yes
    E.2.3.1Full title, date and version of each sub-study and their related objectives

    Other types of substudies
    Specify title, date and version of each substudy with relative objectives: EXPANSION COHORT STUDY
    Primary objective: To define the recommended phase 2 dose (RP2D) and the administration schema of AB8939.
    Secondary objectives:
    To determine the early efficacy of AB8939
    To determine the best regimen for AB8939
    To determine the pharmacokinetic profile in AML patients.

    Altre tipologie di sottostudi
    specificare il titolo, la data e la versione di ogni sottostudio con i relativi obiettivi: COORTE DI ESPANSIONE DELLO STUDIO
    OBIETTIVI
    Obiettivo primario:
    Definire lla dose raccomandata di fase 2 (RP2D) e lo schema di somministrazione di AB8939.
    Obiettivi secondari:
    Determinare l’efficacia precoce di AB8939
    Determinare il regime migliore di AB8939
    Determinare il profilo farmacocinetico in pazienti affetti/e da leucemia mieloide acuta
    E.3Principal inclusion criteria
    1. Patients with a documented diagnosis of acute myeloid leukemia (AML) based on the last version of the World Health Organization classification.
    2. AML patients in second or third line of treatment, if they were eligible to high dose chemotherapy in first line.
    Or AML patients in second line of treatment, if patients were not eligible to high dose chemotherapy in first line.
    A line of treatment is defined as a combination of treatments that ends by a progression of the disease or toxicity related to this treatment
    3. Patients not eligible to hematopoietic stem cell transplantation (HSCT) at the time of inclusion
    4. Patients must be expected to complete the treatment period, in the opinion of the investigator.
    5. Male or non-pregnant female = 18 years old at the time of signing the informed consent.
    6. ECOG performance status = 2
    7. Patients must have adequate organ function without severe heart, lung, liver, kidney or nervous system dysfunction or immune deficiency
    8. In the absence of rapidly progressing disease, the interval from prior treatment to time of AB8939 administration should be at least 14 days.
    9. Adequate recovery, to a maximum of Grade 1 (CTCAE V5.0) from toxicity of prior therapy.
    10. Patients are able to understand, sign, and date the written informed consent form at screening visit prior to any protocol-specific procedures
    11. Patients are able and willing to comply with study procedures as per protocol, including bone marrow biopsies
    1. Pazienti con diagnosi documentata di leucemia mieloide acuta (LMA) o sindrome mielodisplastica (MDS) conformemente all’ultima versione della classificazione dell’Organizzazione Mondiale della Sanità.
    2. Pazienti affetti/e da leucemia mieloide acuta in seconda o terza linea di trattamento, se erano idonei/e alla chemioterapia ad alte dosi come prima linea.
    Oppure pazienti affetti/e da leucemia mieloide acuta in seconda linea di trattamento, se non erano idonei/e alla chemioterapia ad alte dosi come prima linea.
    Oppure pazienti affetti/e da MDS in seconda o terza linea di trattamento e ad alto rischio prognostico in base al sistema di punteggio IPSS-R.
    Una linea di trattamento è definita come una combinazione di trattamenti che termina con una progressione della malattia o con una tossicità correlata a questo trattamento
    3. Pazienti non idonei/e al trapianto di cellule staminali ematopoietiche (HSCT) al momento dell’inclusione
    4. Ci si deve aspettare che i/le pazienti completino il periodo di trattamento, secondo il parere dello sperimentatore.
    5. Maschi o femmine non incinte di età uguale o maggiore di 18 anni al momento della firma del consenso informato.
    6. Stato delle prestazioni ECOG uguali o minori di 1
    7. I/Le pazienti devono avere adeguate funzioni degli organi senza gravi disfunzioni cardiache, polmonari, epatiche, renali o del sistema nervoso o immunodeficienza
    8. In assenza di malattia in rapida progressione, l’intervallo dal trattamento precedente al momento della somministrazione di AB8939 deve essere di almeno 14 giorni.
    9. Recupero adeguato, fino a un massimo di Grado 1 (CTCAE V5.0) dalla tossicità della terapia precedente.
    10. I/Le pazienti devono essere in grado di comprendere, firmare e inserire la data nel modulo di consenso informato scritto alla visita di selezione, prima di prendere parte a qualsivoglia procedura specifica del protocollo
    11. I/Le pazienti devono essere in grado di e disposti/e a rispettare le procedure dello studio come da protocollo, comprese le biopsie del midollo osseo
    E.4Principal exclusion criteria
    1. Patients eligible to a standard of care
    2. Patients eligible to hematopoietic stem cell transplantation (HSCT) at the time of inclusion
    3. Patients diagnosed with acute promyelocytic leukemia (M3)
    4. Patients with clinically active CNS leukemia
    5. Patients with other active malignancies are ineligible unless they have been disease-free for at least 5 years and are deemed by the investigator to be at low risk for recurrence or progression of that malignancy
    6. Patients with major surgery within 28 days prior to the first administration of AB8939
    7. Patients with radiation therapy within 28 days prior to the first administration of AB8939
    8. Patients with HSCT within 100 days prior to the first administration of AB8939
    9. Patients who have received prior standard treatment within 2 weeks or those who have not recovered from adverse events due to treatment administered more than 2 weeks earlier.
    10. Patients who are receiving any other investigational administered with the intention to treat their malignancy within 2 weeks from the last dose prior to entering the study, with the exception of hydroxyurea.
    11. Patients with uncontrolled hypertension e.g. SBP/DBP >149/90 mmHg despite two anti-hypertensive therapy.
    12. Patients with history or evidence of cardiovascular disease such as stroke, ischemic heart disease (myocardial infarction, acute coronary syndrome, unstable angina), heart failure (EF < 50%), conduction disorders (Second degree or third-degree atrioventricular block not successfully treated with a pacemaker, Bi-fascicular block), uncontrolled arrythmia, abnormal QT interval (QTcF > 450 ms for male and >470 ms for female patients), history of torsades de pointes, pericarditis, valvular disease that are not well-controlled.
    13. Patients with history or evidence of renal disease such as severe renal failure defined as creatinine clearance < 30 ml/min.
    14. Patients with history or evidence of neuromuscular disease such as amyotrophic lateral sclerosis, muscular dystrophy, polymyositis, myasthenia gravis, dermatomyositis, sarcopenia.
    15. Patients with history or evidence of CNS disease such as epilepsy, Alzheimer's and other dementias, strokes, migraine and other headaches possibly related to brain tumor or metastasis, multiple sclerosis, Parkinson's disease, neurological infections, brain tumors, sequellae of head injuries and disorders caused by malnutrition.
    16. Patients with diabetes that are not well-controlled by two oral anti-diabetic drugs or insulin with Fasting Blood Glycemia > 110mg/dl and /or HbA1c >7%
    17. Patients with vitamin B12 deficiency, or alcohol addiction
    18. Patients with positive test for active AIDS, Hepatitis B, C, and tuberculosis
    19. Patients with white blood cells count or circulating blasts = 20,000 cells/µL with hydroxyurea at screening
    20. Patients with
    AST and or ALT = 2.5 ULN,Total bilirubin level > 1.5 ULN (except in case of Gilbert’s syndrome but within the limit of 3 x ULN)
    Serum creatinine = 1.5 ULN
    Albumin <30g/l (as AB8939 has a strong plasma protein binding)
    21. Women who are lactating/breastfeeding or who plan to breastfeed while on study
    22. Women with a positive pregnancy test
    23. Men and women of reproductive potential who are unwilling to practice a highly effective method(s) of birth control while on study through through 6months + 5 times plasma half-life of AB8939 for women and 3 months for men after receiving the last dose of study drug
    24. Women planning to become pregnant while on study through 6months + 5 times plasma half-life of AB8939 after receiving the last dose of study drug
    25. Patients likely to not be available to complete all protocol-required study visits or procedures, and/or to comply with all required study procedures to the best of the subject and investigator's knowledge
    26. Patients under psychiatric or, protected by law under guardianship or curatorship, or in emergency situations or, prisoners or, without National Health Insurance
    1. Pazienti ammissibili a uno standard di cura
    2. Pazienti idonei/e al trapianto di cellule staminali ematopoietiche (HSCT) al momento dell’inclusione
    3. Pazienti con diagnosi di leucemia promielocitica acuta (M3)
    4. Pazienti con leucemia dell’SNC clinicamente attiva
    5. I/Le pazienti con altri tumori maligni attivi non possono essere inclusi/e a meno che non siano liberi/e dalla malattia da almeno 5 anni e siano ritenuti/e dallo sperimentatore a basso rischio di recidiva o progressione di tale tumore
    6. Pazienti sottoposti/e a chirurgia importante nei 28 giorni precedenti la prima somministrazione di AB8939
    7. Pazienti sottoposti/e a radioterapia nei 28 giorni precedenti la prima somministrazione di AB8939
    8. Pazienti sottoposti/e a trapianto di cellule staminali ematopoietiche (HSCT) nei 100 giorni precedenti la prima somministrazione di AB8939
    9. Pazienti che hanno ricevuto un precedente trattamento standard nelle 2 settimane precedenti o che non si sono ripresi/e da eventi avversi in seguito a trattamenti somministrati più di 2 settimane prima.
    10. Pazienti che hanno ricevuto qualsiasi altro farmaco sperimentale somministrato con l’intenzione di trattare il loro tumore maligno nelle 2 settimane dall’ultima dose prima di entrare nello studio, ad eccezione dell’idrossiurea.
    11. Pazienti con ipertensione non controllata e.g. SBP/DBP >149/90 mmHg nonostante due trattamenti per l'ipertensione.
    12. Pazienti con anamnesi o evidenza di malattie cardiovascolari come ictus, cardiopatia ischemica (infarto miocardico, sindrome coronarica acuta, angina instabile), insufficienza cardiaca (EF < 50%), disturbi della conduzione (blocco atrioventricolare di secondo o terzo grado non trattato con successo con un pacemaker, blocco bi-fascicolare), aritmia incontrollata, intervallo QT anomalo (QTcF > 450 ms per i pazienti di sesso maschile e >470 ms per quelli di sesso femminile), storia di torsades de pointes, pericardite, malattie valvolari non ben controllate.
    13. Pazienti con anamnesi o evidenza di malattia renale, come l'insufficienza renale grave definita come clearance della creatinina < 30 ml/min.
    14. Pazienti con storia o evidenza di malattia neuromuscolare come sclerosi laterale amiotrofica, distrofia muscolare, polimiosite, miastenia grave, dermatomiosite, sarcopenia.
    15. Pazienti con anamnesi o evidenza di malattie del SNC come epilessia, Alzheimer e altre demenze, ictus, emicrania e altre cefalee possibilmente correlate a tumori o metastasi cerebrali, sclerosi multipla, morbo di Parkinson, infezioni neurologiche, tumori cerebrali, sequele di traumi cranici e disturbi causati da malnutrizione.
    16. Pazienti con diabete non ben controllato da due farmaci antidiabetici orali o dall'insulina con glicemia a digiuno > 110 mg/dl e/o HbA1c >7%.
    17. Pazienti con carenza di vitamina B12 o dipendenza da alcol.
    18. Pazienti con test positivo per AIDS attivo, epatite B, C e tubercolosi.
    19. Pazienti con conta leucocitaria o blasti circolanti = 20.000 cellule/µl con idrossiurea alla selezione
    20. Pazienti con AST e/o ALT = 2,5 ULN, livello di bilirubina totale > 1,5 ULN (eccetto in caso di sindrome di Gilbert ma entro il limite di 3 x ULN) Creatinina sierica = 1,5 ULN Albumina <30g/l
    21. Donne che allattano al seno o che intendono allattare al seno durante la loro partecipazione allo studio
    22. Donne con test di gravidanza positivo
    23. Uomini e donne in età fertile che non sono disposti a utilizzare uno o più metodi contraccettivi altamente efficaci durante lo studio per 6 mesi + 5 volte il periodo di emivita plasmatica di AB8939 per le donne e 3 mesi per gli uomini, dopo aver ricevuto l’ultima dose del farmaco oggetto dello studio
    24. Donne che stanno pianificando una gravidanza durante lo studio per 6 mesi + 5 volte il periodo di emivita plasmatica di AB8939 dopo aver ricevuto l’ultima dose del farmaco oggetto dello studio
    25. Pazienti probabilmente non disponibili a completare tutte le visite o procedure di studio richieste dal protocollo e/o a conformarsi a tutte le procedure di studio richieste al meglio delle conoscenze del soggetto e dello sperimentatore
    26. Pazienti psichiatrici/he o protetti/e per legge da tutori o curatori, pazienti in situazioni di emergenza, detenuti/e e pazienti senza assicurazione sanitaria nazionale.
    E.5 End points
    E.5.1Primary end point(s)
    Rate of dose-limiting toxicity (DLT)
    Livello di tossicità dose-limitante (DLT)
    E.5.1.1Timepoint(s) of evaluation of this end point
    Day 28
    28 giorni
    E.5.2Secondary end point(s)
    To determine the rate and the duration of CR, CRi, CRMRD-,
    Rate of PR, ORR
    PK parameters: Tmax, Cmax, AUC0-t, AUC0-inf, t1/2, Cl, Vd, after the first administration to 6 patients at a dose-level.
    Response rate based on the subtype of leukemia and classification on risk-status (WHO classification, NCCN guidelines, ELN risk stratification by genetics (Döhner,blood 2017), caryotype and molecular studies by targeted NGS).
    Parametri farmacocinetici: Tmax, Cmax, AUC0-t, AUC0-inf, t1/2, Cl, Vd dopo la prima somministrazione per tutti/e i/le pazienti.
    Tasso di risposta oggettiva (ORR)
    Tasso e durata di CR, CRi, CRMRD-, PR, HI, e MLFS
    Tasso di risposta basato sul sottotipo di leucemia, stato di rischio e anomalie genetiche.
    E.5.2.1Timepoint(s) of evaluation of this end point
    Day 28
    28 giorni
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy No
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic Yes
    E.6.7Pharmacodynamic No
    E.6.8Bioequivalence No
    E.6.9Dose response Yes
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) Yes
    E.7.1.1First administration to humans Yes
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) Yes
    E.7.3Therapeutic confirmatory (Phase III) No
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled No
    E.8.1.1Randomised No
    E.8.1.2Open No
    E.8.1.3Single blind No
    E.8.1.4Double blind No
    E.8.1.5Parallel group No
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo No
    E.8.2.3Other No
    E.8.2.4Number of treatment arms in the trial1
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned3
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA15
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA Information not present in EudraCT
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    Canada
    United States
    France
    Greece
    Spain
    E.8.7Trial has a data monitoring committee No
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    LVLS
    LVLS
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years2
    E.8.9.1In the Member State concerned months0
    E.8.9.1In the Member State concerned days0
    E.8.9.2In all countries concerned by the trial years2
    E.8.9.2In all countries concerned by the trial months0
    E.8.9.2In all countries concerned by the trial days0
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 82
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 20
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations No
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception No
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state30
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 60
    F.4.2.2In the whole clinical trial 102
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    None
    Nessuno
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2024-02-16
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2023-07-05
    P. End of Trial
    P.End of Trial StatusPrematurely Ended
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 09 23:19:15 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA